Welcome to our dedicated page for Anika Therapeutics news (Ticker: ANIK), a resource for investors and traders seeking the latest updates and insights on Anika Therapeutics stock.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global joint preservation company focused on early intervention orthopedics, osteoarthritis (OA) pain management, and regenerative solutions based on hyaluronic acid and implant technologies. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Anika’s clinical programs, product portfolio, and financial performance evolve over time.
News about Anika commonly covers quarterly and annual financial results, including performance in its Commercial Channel and OEM Channel, as well as commentary on operating expenses, cost-saving measures, and capital allocation decisions such as share repurchase programs. Investors can also find updates on governance and compensation topics, including amendments to equity incentive plans and inducement grants made under Nasdaq Listing Rule 5635(c)(4).
A significant portion of Anika’s news flow focuses on clinical and regulatory milestones for its key products. Examples include updates on the U.S. pivotal Phase III FastTRACK study for the Hyalofast cartilage repair scaffold, the filing of the third and final PMA module for Hyalofast with the U.S. Food and Drug Administration, and progress toward a U.S. New Drug Application for Cingal, the company’s non-opioid, single-injection OA pain management product. Releases also describe commercial milestones, such as Cingal surpassing one million injections worldwide and the growth trajectory of the Integrity Implant System.
Corporate and leadership developments are another recurring theme. Anika issues press releases on planned leadership transitions, board changes, and strategic refocusing around its hyaluronic acid portfolio and regenerative solutions. By reviewing the ANIK news stream on this page, readers can monitor how clinical data, regulatory submissions, commercial performance, and governance actions shape the company’s position in osteoarthritis pain management and orthopedic regenerative medicine.
Anika Therapeutics (NASDAQ: ANIK) announced plans to release its fourth quarter and year-end 2022 financial results on March 6, 2023, after market close. A conference call is scheduled for the same day at 5:00 p.m. ET to discuss these results and business highlights. Investors can access the call by dialing the provided numbers or through a live audio webcast on Anika's website. Anika Therapeutics focuses on joint preservation and orthopedic care, delivering innovative solutions in areas such as osteoarthritis and sports medicine. Further information and an accompanying slide presentation will be available online.
Anika Therapeutics (NASDAQ: ANIK) addressed a letter from Caligan Partners LP, highlighting their recent strategic discussions and growth initiatives. Over six months, Anika's Board engaged with Caligan eight times, emphasizing confidence in a strategy that expands its market opportunity from $1 billion to over $8 billion. The firm continues to leverage its leadership in osteoarthritis pain management, which supports investments in regenerative and joint preservation products. Anika's stock has risen approximately 40% since June 2022, outperforming the NASDAQ Composite by 42%. The fourth quarter and year-end financial results will be announced on March 6, 2023.
Caligan Partners LP, a significant shareholder of Anika Therapeutics (NASDAQ: ANIK), has publicly criticized the current board for strategic missteps and poor capital allocation, contributing to the company's underperformance. In a letter dated February 21, 2023, Caligan highlighted the substantial losses in Anika's joint preservation segment and the failure to leverage its viscosupplement portfolio effectively. They are advocating for a strategic review and have proposed three specific actions aimed at driving significant changes to enhance shareholder value.
Anika Therapeutics has launched the RevoMotion Reverse Shoulder Arthroplasty System, expanding its portfolio in the $800 million U.S. reverse shoulder market. The system features the industry's smallest diameter threaded glenoid baseplate, which enhances bone preservation and surgical flexibility. It aims to increase efficiency in operating rooms with streamlined instrument trays and is designed to meet a growing demand for shoulder arthroplasty procedures, projected at 200,000 for the U.S. in 2023. The limited market release is currently underway, with a full release expected in late 2023.
Anika Therapeutics reported a 2% revenue growth for Q3 2022, totaling $40.3 million. Key product segments included OA Pain Management at $25.7 million (down 2%) and Non-Orthopedic revenue at $2.8 million (up 27%). The company experienced a net loss of $4.2 million or $(0.29) per share, compared to net income of $0.6 million in Q3 2021. Notably, the Phase III trial for Cingal achieved primary endpoints, demonstrating superiority over steroid treatment. The Hyalofast trial is nearing full enrollment, and the company remains on track to meet FY2022 guidance.
Anika Therapeutics announced that Cingal met its primary endpoint in a Phase III study, showing superiority over steroid alone for osteoarthritis pain relief at 26 weeks. With a 71% mean pain improvement, Cingal combines hyaluronic acid with a steroid, and is already commercialized in over 35 countries. Anika plans to engage the FDA for U.S. approval and explore partnerships for Cingal's advancement in the U.S. and Asia. This study builds on prior Phase III results and positions Anika for significant market opportunities, addressing an unmet need for the 32 million osteoarthritis patients in the U.S.
Anika Therapeutics, Inc. (NASDAQ: ANIK) will release its third quarter 2022 financial results after market close on November 8, 2022. The company will host a conference call on the same day at 5:00 p.m. ET to discuss these results and highlight business developments. Interested parties can join via phone or listen to a live audio webcast on Anika's Investor Relations webpage. Anika focuses on innovative orthopedic care, particularly in joint preservation, leveraging hyaluronic acid and implant solutions.
Anika Therapeutics announces the limited market release of its X-Twist Fixation System, a new cornerstone suture anchor designed for key orthopedic repairs, including rotator cuff and ankle stabilization. The first surgeries were performed by Dr. Christopher E. Baker in Tampa, Florida. This system offers both knotless and traditional knotted options, enhancing usability for surgeons. Following FDA 510(k) clearance in May 2022, Anika aims for a broader U.S. launch in 2023, reinforcing its commitment to expanding its sports medicine portfolio within an $8 billion market.
Anika Therapeutics reported a 4% revenue increase in Q2 2022, totaling $39.7 million compared to $38.1 million in the same quarter of 2021. Key revenue segments included OA Pain Management at $25.7 million (6% up) and Joint Preservation and Restoration at $12.1 million (2% up). However, the company posted a net loss of $2.8 million, down from a net income of $6.5 million a year prior. Gross margin stood at 63%, with adjusted gross margin at 67%. The FDA granted 510(k) clearance for the X-Twist Fixation System, with a limited release planned for the second half of 2022, signaling potential growth avenues ahead.
Anika Therapeutics (NASDAQ: ANIK) has received the ACE Award from the AOSSM for its Tactoset Injectable Bone Substitute. This calcium phosphate-based product, enhanced with hyaluronic acid, improves the management of inferior bone quality, crucial for successful surgical interventions such as rotator cuff repairs. It doubles the pull-out strength of suture anchors in osteoporotic bone models, highlighting its efficacy. Launched in 2019 and FDA-cleared in 2021, Tactoset offers a simpler solution for surgeons, addressing microfractures without the need for larger hardware.